8-K
filed June 13, 2024, 7:59 PM ET
ticker RGNX
CIK 0001590877
leadership
confidence high
sentiment neutral
materiality 0.65
REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman
REGENXBIO Inc.
- Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.
- Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.
- Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).
- Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.
- Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Daniel Tassé was appointed as Lead Independent Director at REGENXBIO Inc..
- Action
- appointed
- Role
- Lead Independent Director
Exact text from the filing
Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Curran M. Simpson was appointed as President and Chief Executive Officer at REGENXBIO Inc..
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
the Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Curran M. Simpson was appointed as Class I director at REGENXBIO Inc..
- Action
- appointed
- Role
- Class I director
Exact text from the filing
In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jerry Karabelas departed as Lead Independent Director at REGENXBIO Inc..
- Action
- succeeded
- Role
- Lead Independent Director
Exact text from the filing
Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Kenneth T. Mills was appointed as Chairman of the Board at REGENXBIO Inc..
- Action
- appointed
- Role
- Chairman of the Board
Exact text from the filing
accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.